Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
2.120
+0.040 (1.92%)
At close: Sep 15, 2026, 4:00 PM EDT
2.130
+0.010 (0.47%)
After-hours: Sep 15, 2026, 5:41 PM EDT
Jyong Biotech Earnings Call Transcripts
Fiscal Year 2026
-
MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.